PBPH vs PSIL

PBPHBPortfolio Building Block World Pharma and Biotech Index ETF

PSILFAdvisorShares Psychedelics ETF

In short

PBPH Most biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

PSIL The ticker is the thesis. PSIL is a compact, global, actively run basket of health care companies working on psychedelic medicine, with a stated goal of long-term capital appreciation in a corner of the market almost no other ETF touches.

Stated mandate

PBPH The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

PSIL The Fund seeks long-term capital appreciation.

Why people hold it

• PBPH 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
• Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
• Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
• Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.

• PSIL One ticker, the whole theme: a global basket of roughly two dozen health care names tied to psychedelic medicine, instead of hand-picking single clinical-stage stocks.advisorshares.com
• Concentrated on purpose. At around 25 positions, the theme stays front and center rather than getting diluted inside a broad mega-cap pharma index.
• Trading since 2021, so there is multi-year live operating history behind the strategy, not a simulated one.

Worth knowing

• PBPH One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
• Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
• Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.

• PSIL Expensive by pharma-ETF standards: 1.84% a year, against 0.36% at PPH and 0.35% at XPH. A niche, actively managed mandate carries a niche price tag.
• Small asset base and light trading volume. Spreads can be wide, so limit orders are the standard way to deal with a fund this thinly traded.
• Within its pharma and therapeutics peer group it sits in the bottom quartile, held back mainly by cost and tradability rather than the theme itself.

Full PBPH profile⁠

Full PSIL profile⁠